TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
A user who buzzed their hair, raising their confidence. Other users suggested trying finasteride to thicken the existing hair or using hair systems as an alternative. Additionally, toppik was suggested as a way to fill in thinning areas.
HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.
User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
A user shared their 14-day recovery progress after a 3450 graft FUE hair transplant in Turkey, noting faster healing possibly due to hydrolyzed collagen supplements. They asked if others had similar experiences with or without such supplements.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.
Epibiotech will offer off-the-shelf allogeneic hair multiplication treatment in South Korea, using dermal papilla cells from donors to grow hair in balding areas. This method is cheaper and less invasive than traditional hair transplants.
Fatty acid metabolic signaling can activate epithelial stemcells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.
The conversation discusses new hair loss treatments like stemcell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.
Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.
A 28-year-old man shared his experience with a 2990 graft FUE hair transplant at HDC Clinic in Cyprus, praising the professionalism and care received. He has been using topical Minoxidil, Biotin, Dermarolling, and recently started Finasteride and oral Minoxidil.
PP405 shows promise for hair regrowth by manipulating stemcell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
Stemcell hair restoration lacks scientific evidence and is often considered a scam. Effective hair loss treatments include hair transplants, Minoxidil, and Finasteride, but stemcell treatments are not proven.
Pelage is developing a topical hair follicle stemcell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
A stemcell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stemcells. The drug is in the formulation development stage, targeting markets like the US and Korea.
A potential treatment for hair loss that involves injecting fat into the scalp; the role of testosterone and estrogen in thinning fat tissue under the skin; research on using lard to treat androgenic alopecia, as well as PRP + ACELL/amniotic stemcell treatments; and ongoing clinical trials by doctors involved in the study.
Exosome treatment for hair loss, derived from umbilical cord stemcells, is being considered as an option before a hair transplant. Users discuss the need for ongoing maintenance and share experiences with different exosome sources, including plant-derived options.
The conversation discusses the progress and potential of hair cloning by Stemson Therapeutics, questioning if it will be realized in the next 5-10 years or if it's just false hope. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stemcells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
A new "third cell" discovery in Japan could be key to fully regenerating hair follicles, with human trials possibly starting in 2027-2028. AI is expected to accelerate medical discoveries, potentially leading to a hair loss cure within a few years.
Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.
A Swiss product called Redensyl, which is supposed to target hair follicle stemcells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.
Stemson raised $15M for hair cloning, with hopes it becomes a reality in 10-20 years. Users are hopeful and discuss using Minoxidil and finasteride in the meantime.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.